Literature DB >> 8421601

Position specificity of Ki-ras oncogene mutations during the progression of colorectal carcinoma.

C F Rochlitz1, I Heide, E de Kant, R Böhmer, F J Peter, P Neuhaus, D Huhn, R Herrmann.   

Abstract

The Ki-ras proto-oncogene is converted into an active oncogene by mutations in codon 12, 13, or 61. The incidence of mutations in the Ki-ras oncogene in colorectal adenomas and primary colorectal carcinomas has been shown to be 50-75 and 40-65%, respectively. To determine the role activation of the Ki-ras oncogene plays in the progression of colorectal carcinoma, we analyzed DNA from 11 nude-mouse xenografts and from 24 metastases of 22 patients with colorectal carcinoma, using the polymerase chain reaction technique and hybridization with labeled mutation-specific oligomers. Eleven of the 24 metastases (46%) carried mutations, 7 in codon 12 and 4 in codon 13, whereas only 1 nude-mouse tumor (9%) harbored a Ki-ras codon-12 mutation. Eleven of these 12 mutations in advanced stages of colorectal cancer were localized to the second position of either codon 12 or codon 13, whereas a majority of published ras mutations in earlier stages are in the first position of codon 12 of the Ki-ras oncogene. We conclude that there is a position specificity of Ki-ras oncogene mutations in advanced stages of colorectal carcinoma. In general, however, these mutations do not seem to play an important role in the progression of this cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8421601     DOI: 10.1159/000227150

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  6 in total

1.  MDR1 expression correlates with mutant p53 expression in colorectal cancer metastases.

Authors:  E de Kant; I Heide; C Thiede; R Herrmann; C F Rochlitz
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

2.  Simple and sensitive detection of mutations in the ras proto-oncogenes using PNA-mediated PCR clamping.

Authors:  C Thiede; E Bayerdörffer; R Blasczyk; B Wittig; A Neubauer
Journal:  Nucleic Acids Res       Date:  1996-03-01       Impact factor: 16.971

Review 3.  A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.

Authors:  Vanessa Deschoolmeester; Marc Baay; Pol Specenier; Filip Lardon; Jan B Vermorken
Journal:  Oncologist       Date:  2010-06-28

4.  K-ras mutations in sporadic colorectal tumors in Israel: unusual high frequency of codon 13 mutations and evidence for nonhomogeneous representation of mutation subtypes.

Authors:  Dmitry Kislitsin; Aaron Lerner; Gad Rennert; Zeev Lev
Journal:  Dig Dis Sci       Date:  2002-05       Impact factor: 3.199

5.  Molecular alterations in a patient with Turcot's syndrome.

Authors:  C F Rochlitz; I Heide; E de Kant; A Neubauer; C A Schmidt; P Neuhaus; D Huhn; R Herrmann
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

Review 6.  Prognostic and predictive roles of KRAS mutation in colorectal cancer.

Authors:  Amanda K Arrington; Eileen L Heinrich; Wendy Lee; Marjun Duldulao; Supriya Patel; Julian Sanchez; Julio Garcia-Aguilar; Joseph Kim
Journal:  Int J Mol Sci       Date:  2012-09-25       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.